Evidence map›Paper›PMID 39226456›Full record

ArticleBlood advances2024

Mitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer-associated fibroblasts.

Richard J Burt, Aditi Dey, Ayse Akarca, Hermione Allen, Rodothea Amerikanou, Samantha Atkinson, David Auty, Jenny Chatzigerou, Emily Cutler, Jose Afonso Guerra-Assuncao and 6 more

Abstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Mitochondrial RNA in Inflammation.International journal of biological sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Richard J BurtUniversity College London, Cancer Institute, London, United Kingdom.
Aditi DeyUniversity College London, Cancer Institute, London, United Kingdom.ORCID 0009-0008-0402-1307
Ayse AkarcaUniversity College London, Cancer Institute, London, United Kingdom.
Hermione AllenUniversity College London, Cancer Institute, London, United Kingdom.ORCID 0009-0006-1884-1395
Rodothea AmerikanouUniversity College London, Cancer Institute, London, United Kingdom.ORCID 0000-0001-6691-9210
Samantha AtkinsonThe Francis Crick Institute, London, United Kingdom.
David AutySchool of Forestry, Northern Arizona University, Flagstaff, AZ.
Jenny ChatzigerouHull York Medical School, University of York, United Kingdom.ORCID 0009-0008-0063-0295
Emily CutlerUniversity College London, Cancer Institute, London, United Kingdom.
Jose Afonso Guerra-AssuncaoUniversity College London, Great Ormond Street Institute of Child Health, London, United Kingdom.
Kristina KirschnerCancer Research UK Scotland Institute, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0001-7607-8670
Ruchi KumariCancer Research UK Scotland Institute, University of Glasgow, Glasgow, United Kingdom.
Jiten ManjiUniversity College London, Cancer Institute, London, United Kingdom.
Teresa MarafiotiUniversity College London, Cancer Institute, London, United Kingdom.ORCID 0000-0003-1223-6275
Juma WardUniversity College London, Cancer Institute, London, United Kingdom.
Adele K FieldingUniversity College London, Cancer Institute, London, United Kingdom.ORCID 0000-0002-4746-7789

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractCancer-associated fibroblasts (CAFs) arising from bone marrow-derived mesenchymal stromal cells (MSCs) are prominent in B-cell precursor acute lymphoblastic leukemia (B-ALL). We have previously shown that CAF formation is triggered by exposure to reactive oxygen species-inducing chemotherapy and that CAFs support chemoresistance by donating mitochondria to the cancer cells through tunneling nanotubes. In the present study, we show that exposure of MSCs to ALL cell lines, patient-derived xenografts, and primary cells or their conditioned media can also trigger CAF formation. Using bulk RNA sequencing in cell lines, we show that the MSC to CAF transition is accompanied by a robust interferon pathway response, and we have validated this finding in primary cells. Using confocal microscopy and flow cytometry, we identify the uptake of leukemia cell-derived mitochondrial double-stranded RNA (dsRNA) by MSCs as a proximate trigger for the MSC to CAF transition. We demonstrate that inhibiting dsRNA formation in ALL cells by treatment with low-dose ethidium bromide or the mitochondrial transcription inhibitor IMT1, or degrading dsRNA in conditioned media by 100°C exposure eliminates the ability of the ALL conditioned media to stimulate MSC to CAF transition. Our data reveal, to our knowledge, a novel and previously undescribed mechanism by which cancer cells induce a CAF phenotype in stromal cells, showing how B-ALL cells can directly induce the previously described niche-mediated protection within the bone marrow.

Indexed as

Cancer-Associated FibroblastsMesenchymal Stem CellsMitochondriaRNA, Double-StrandedAnimalsCell Line, TumorCulture Media, ConditionedHumansMicePrecursor B-Cell Lymphoblastic Leukemia-LymphomaCulture Media, ConditionedRNA, Double-Stranded

Identifiers

PMID39226456
PMCPMC11570786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.